Latest & greatest articles for copd exacerbations

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd exacerbations or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd exacerbations and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd exacerbations

21. The inflammasome pathway in stable COPD and acute exacerbations

The inflammasome pathway in stable COPD and acute exacerbations 27730204 2018 11 13 2312-0541 2 3 2016 Jul ERJ open research ERJ Open Res The inflammasome pathway in stable COPD and acute exacerbations. 00002-2016 Chronic obstructive pulmonary disease (COPD) is characterised by pulmonary and systemic inflammation that bursts during exacerbations of the disease (ECOPD). The NLRP3 inflammasome is a key regulatory molecule of the inflammatory response. Its role in COPD is unclear. We investigated (...) the NLRP3 inflammasome status in: 1) lung tissue samples from 38 patients with stable COPD, 15 smokers with normal spirometry and 14 never-smokers; and 2) sputum and plasma samples from 56 ECOPD patients, of whom 41 could be reassessed at clinical recovery. We observed that: 1) in lung tissue samples of stable COPD patients, NLRP3 and interleukin (IL)-1β mRNA were upregulated, but both caspase-1 and ASC were mostly in inactive form, and 2) during infectious ECOPD, caspase-1, oligomeric ASC

ERJ open research2016 Full Text: Link to full Text with Trip Pro

22. Another Choice for Prevention of COPD Exacerbations.

Another Choice for Prevention of COPD Exacerbations. Another Choice for Prevention of COPD Exacerbations. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27181835 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jun 9;374(23):2284-6. doi: 10.1056/NEJMe1604444. Epub 2016 May 15. Another Choice for Prevention of COPD Exacerbations. 1 . 1 From the Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill. Comment on [N Engl J Med. 2016] PMID: 27181835 DOI

NEJM2016

23. Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit

Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit 27730166 2018 11 13 2312-0541 2 1 2016 Jan ERJ open research ERJ Open Res Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit. 00034-2015 Chronic obstructive pulmonary disease (COPD) care across Europe has high heterogeneity with respect to cost and the services available. Variations in length of stay (LOS) may be attributed to patient characteristics, resource (...) and organisational characteristics, and/or the so-called hospital cluster effect. The European COPD Audit in 13 countries included data from 16 018 hospitalised patients. The recorded variables included information on patient and disease characteristics, and resources available. Variables associated with LOS were evaluated by a multivariate, multilevel analysis. Mean±sd LOS was 8.7±8.3 days (median 7 days, interquartile range 4-11 days). Crude variability between countries was reduced after accounting

ERJ open research2016 Full Text: Link to full Text with Trip Pro

24. Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD

Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD 26769015 2016 01 15 2016 05 17 2016 11 26 1468-3296 71 2 2016 Feb Thorax Thorax Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD. 133-40 10.1136/thoraxjnl-2015-207775 Hospitalisation due to acute exacerbations of COPD (AECOPD) is common, and subsequent mortality high. The DECAF score was derived for accurate prediction of mortality and risk stratification (...) Kingdom epidemiology PMC4752621 COPD Exacerbations 2016 1 16 6 0 2016 1 16 6 0 2016 5 18 6 0 ppublish 26769015 thoraxjnl-2015-207775 10.1136/thoraxjnl-2015-207775 PMC4752621

EvidenceUpdates2016

25. Randomised controlled trial: LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients

Randomised controlled trial: LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients Article Text Therapeutics/Prevention Randomised controlled trial LABA/LAMA combinations instead of LABA/ICS combinations may

Evidence-Based Medicine (Requires free registration)2016

26. Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption with no increase in rates of treatment failure or mortality

Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption with no increase in rates of treatment failure or mortality BestBets: Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption with no increase in rates of treatment failure or mortality Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption (...) of chronic obstructive pulmonary disease (COPD)] can [use of a procalcitonin algorithm compared to physician gestalt] result in [lower rates of antibiotic consumption with no adverse effects] Clinical Scenario A 78 year old female presents to your emergency department reporting increased wheezing over the last 24 hours. She reports a mildly productive cough and denies fever. A chest x-ray reveals no clear evidence of pneumonia. In addition to therapy for what you believe is a COPD exacerbation, you consider the possibility

BestBETS2015

27. In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia?

In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? BestBets: In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? Report By: Mark Woods - Consultant in Emergency Medicine Search checked by David Hodgson - ST5 Emergency Medicine Institution: Whiston (...) Hospital, Merseyside, UK and Mersey School of Emergency Medicine, UK Date Submitted: 31st August 2012 Date Completed: 10th March 2015 Last Modified: 11th March 2015 Status: Green (complete) Three Part Question In [patients with an Acute Exacerbation of COPD] can a [normal venous blood gas CO2] [rule out arterial hypercarbia]? Clinical Scenario A 74 year old male patient with known COPD presents acutely breathless with widespread wheeze. He refuses an arterial blood gas (ABG) and complains that last

BestBETS2015

28. Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis

Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis

Health Quality Ontario2015

29. Prevention of Acute Exacerbations of COPD

Prevention of Acute Exacerbations of COPD 894 Evidence-Based Medicine [ 147#4 CHEST APRIL 2015 ] P r e v en tio n o f A c u t e Exacerba tio n s o f C O PD American College of Chest Physicians and Canadian Th oracic Society Guideline Gerard J. Criner , MD, FCCP ; Jean Bourbeau , MD, FCCP ; Rebecca L. Diekemper , MPH ; Daniel R. Ouellette , MD, FCCP ; Donna Goodridge , RN, PhD ; Paul Hernandez , MDCM ; Kristen Curren , MA ; Meyer S. Balter , MD, FCCP ; Mohit Bhutani , MD, FCCP ; Pat G. Camp (...) the rest of the world. An exacerbation of COPD (periodic escalations of symptoms of cough, dyspnea, and sputum production) is a major contributor to worsening lung function, impairment in quality of life, need for urgent care or hospitalization, and cost of care in COPD. Research conducted over the past decade has contributed much to our current understanding of the pathogenesis and treatment of COPD. Additionally, an evolving literature has accumu- lated about the prevention of acute exacerbations

American College of Chest Physicians2015

30. Executive Summary: Prevention of Acute Exacerbation of COPD

Executive Summary: Prevention of Acute Exacerbation of COPD 883 journal.publications.chestnet.org E x e c u t i v e S umm a r y Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Th oracic Society Guideline Gerard J. Criner , MD, FCCP ; Jean Bourbeau , MD, FCCP ; Rebecca L. Diekemper , MPH ; Daniel R. Ouellette , MD, FCCP ; Donna Goodridge , RN, PhD ; Paul Hernandez , MDCM ; Kristen Curren , MA ; Meyer S. Balter , MD, FCCP ; Mohit Bhutani , MD, FCCP (...) -Based Medicine [ 147#4 CHEST APRIL 2015 ] health-care expenditures, $8.0 billion in indirect morbidity costs, and $12.4 billion in indirect mortality costs. 9 Exacerbations account for most of the morbidity, mortality, and costs associated with COPD. The economic burden associated with moderate and severe exacerbations in Canada has been estimated to be in the range of $646 million to $736 million per annum. 10 Th is value may be an underestimate given that the prevalence of moderate exacerbations is not well

American College of Chest Physicians2015

31. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. 25196117 2014 10 02 2014 10 14 2015 11 19 1533-4406 371 14 2014 Oct 02 The New England journal of medicine N. Engl. J. Med. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. 1285-94 10.1056/NEJMoa1407154 Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the (...) benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored. In this 12-month, double-blind, parallel-group study, 2485 patients with a history of exacerbation of COPD received triple therapy consisting of tiotropium (at a dose of 18 μg once daily), salmeterol (50 μg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 μg twice daily) during a 6-week run-in period. Patients were then randomly assigned to continued triple therapy

NEJM2014

32. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. BACKGROUND: Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored. METHODS: In this 12-month, double-blind, parallel-group study, 2485 patients with a history (...) of exacerbation of COPD received triple therapy consisting of tiotropium (at a dose of 18 μg once daily), salmeterol (50 μg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 μg twice daily) during a 6-week run-in period. Patients were then randomly assigned to continued triple therapy or withdrawal of fluticasone in three steps over a 12-week period. The primary end point was the time to the first moderate or severe COPD exacerbation. Spirometric findings, health status, and dyspnea

NEJM2014

33. Should you consider antibiotics for exacerbations of mild COPD?

Should you consider antibiotics for exacerbations of mild COPD? Should you consider antibiotics for exacerbations of mild COPD? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Should you consider antibiotics for exacerbations of mild COPD? View/ Open Date 2014-04 Format Metadata Abstract Consider antibiotics (...) for patients with exacerbations of mild to moderate chronic obstructive pulmonary disease (COPD). URI Part of Citation Journal of Family Practice, 64(4): 2014: E11-E13 Collections hosted by hosted by

PURLS2014

34. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index

Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index 24077342 2014 06 11 2014 06 24 2014 08 11 1931-3543 145 5 2014 May Chest Chest Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. 972-80 No valid tools exist for evaluating the prognosis in the short and medium term after hospital discharge of patients with COPD. Our hypothesis was that a new index based on the CODEX (comorbidity, obstruction, dyspnea (...) , and previous severe exacerbations) index can accurately predict mortality, hospital readmission, and their combination for the period from 3 months to 1 year after discharge in patients hospitalized for COPD. A multicenter study of patients hospitalized for COPD exacerbations was used to develop the CODEX index, and a different patient cohort was used for validation. Comorbidity was measured using the age-adjusted Charlson index, whereas dyspnea, obstruction, and severe exacerbations were calculated

EvidenceUpdates2014

35. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD.

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. BACKGROUND: Retrospective studies have shown that statins decrease the rate and severity of exacerbations, the rate of hospitalization, and mortality in chronic obstructive pulmonary disease (COPD). We prospectively studied the efficacy of simvastatin in preventing exacerbations in a large, multicenter, randomized trial. METHODS: We designed the Prospective Randomized Placebo-Controlled Trial of Simvastatin (...) in the Prevention of COPD Exacerbations (STATCOPE) as a randomized, controlled trial of simvastatin (at a daily dose of 40 mg) versus placebo, with annual exacerbation rates as the primary outcome. Patients were eligible if they were 40 to 80 years of age, had COPD (defined by a forced expiratory volume in 1 second [FEV1] of less than 80% and a ratio of FEV1 to forced vital capacity of less than 70%), and had a smoking history of 10 or more pack-years, were receiving supplemental oxygen or treatment

NEJM2014

36. Systematic review and meta-analysis: Long-term antibiotic therapy reduces exacerbation frequency in patients with COPD but it remains unclear which patients to target

Systematic review and meta-analysis: Long-term antibiotic therapy reduces exacerbation frequency in patients with COPD but it remains unclear which patients to target Long-term antibiotic therapy reduces exacerbation frequency in patients with COPD but it remains unclear which patients to target | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long-term antibiotic therapy reduces exacerbation frequency in patients with COPD but it remains unclear which patients to target Article Text Therapeutics Systematic review and meta-analysis Long-term antibiotic

Evidence-Based Medicine (Requires free registration)2014

37. Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD.

Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD. 24836125 2014 06 06 2014 06 10 2017 02 20 1533-4406 370 23 2014 Jun 05 The New England journal of medicine N. Engl. J. Med. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. 2201-10 10.1056/NEJMoa1403086 Retrospective studies have shown that statins decrease the rate and severity of exacerbations, the rate of hospitalization, and mortality in chronic obstructive pulmonary disease (COPD). We (...) prospectively studied the efficacy of simvastatin in preventing exacerbations in a large, multicenter, randomized trial. We designed the Prospective Randomized Placebo-Controlled Trial of Simvastatin in the Prevention of COPD Exacerbations (STATCOPE) as a randomized, controlled trial of simvastatin (at a daily dose of 40 mg) versus placebo, with annual exacerbation rates as the primary outcome. Patients were eligible if they were 40 to 80 years of age, had COPD (defined by a forced expiratory volume in 1

NEJM2014 Full Text: Link to full Text with Trip Pro

39. Comorbidities and Short-term Prognosis in Patients Hospitalized for Acute Exacerbation of COPD: The EPOC en Servicios de Medicina Interna (ESMI) Study

Comorbidities and Short-term Prognosis in Patients Hospitalized for Acute Exacerbation of COPD: The EPOC en Servicios de Medicina Interna (ESMI) Study 23303399 2013 01 10 2013 02 11 2015 11 19 1931-3543 142 5 2012 Nov Chest Chest Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study. 1126-33 10.1378/chest.11-2413 Comorbidities are frequent in patients hospitalized for COPD exacerbation, but little (...) is known about their relation with short-term mortality and hospital readmissions. Our hypothesis is that the frequency and type of comorbidities impair the prognosis within 12 weeks after discharge. A longitudinal, observational, multicenter study of patients hospitalized for a COPD exacerbation with spirometric confirmation was performed. Comorbidity information was collected using the Charlson index and a questionnaire that included other common conditions not included in this index. Dyspnea

EvidenceUpdates2013

40. Herbal Therapy and Stable COPD: Delaying Onset and Duration of Acute Exacerbations with Supplementation to Baseline Therapy

Herbal Therapy and Stable COPD: Delaying Onset and Duration of Acute Exacerbations with Supplementation to Baseline Therapy "Herbal Therapy and Stable COPD: Delaying Onset and Duration of Acute E" by Amy M. Hernandez < > > > > > Title Author Date of Award Fall 10-18-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Patients with chronic obstructive pulmonary disease (COPD) experience progressive pulmonary decline (...) with each acute exacerbation of disease. Current therapy is focused on treating acute symptoms of COPD, but there are no medications that have been implemented to delay the progression of the disease. Herbal therapies have been developed by researchers to supplement baseline therapy for COPD with the goal of prolonging healthful pulmonary states, thereby slowing disease progression. Methods: Exhaustive search of available medical literature from Medline, CINAHL, Web of Science, EBMR and NIH websites

Pacific University EBM Capstone Project2013